Upstream Bio Inc (UPB)
Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, with an emphasis on severe respiratory disorders. Its lead product candidate, verekitug, is being evaluated in Phase 2 studies for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease, and is also in a Phase I trial for chronic obstructive pulmonary disease. Founded in 2021, the company is headquartered in Waltham, Massachusetts. Upstream Bio’s common stock is listed on the NASDAQ under the symbol UPB.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-UPB
|
$8.04
|
15.7% Upside
|
Fair
|
$38.25
|
450.4% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-2.4x
|
1.3x
|
114.7x
|
379.9 M
|
87.475 M
|
0.3%
|
74.5%
|
13.9
|
—
|
89.4%
|
